[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 221
1. Pasetto LM, Falci C, Rizzo E, De Salvo GL, Gasparini G, D'Andrea M, Bajetta E, Platania M, Alabiso O, Miraglia S, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Giordano M, Luchena G, Buzzi F, Ricotta R, Siena S, Monfardini S: Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Res; 2008 May-Jun;28(3B):1813-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.
  • BACKGROUND: Palliative chemotherapy significantly reduces mortality in patients with stage IV colon cancer, but is less prescribed with rising age.
  • PATIENTS AND METHODS: From January to December 2004, 78 files on the management of stage IV colorectal cancer (CRC) patients over 70 years, collected from 10 Italian Centres, were retrospectively examined.
  • CONCLUSION: In Italy, a proportion of elderly patients with metastatic chemonaive CRC are usually treated with a tolerability and overall survival similar to those for the younger population.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Italy. Leucovorin / administration & dosage. Male. Medical Oncology / methods. Mitomycin / administration & dosage. Neoplasm Staging. Oncology Service, Hospital. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630465.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol
  •  go-up   go-down


2. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol; 2005 Oct;167(4):969-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
  • The biological effects of STAT3 have not been studied extensively in the pathogenesis of colon cancer, nor has the role of Janus kinase 3 (JAK3), the physiological activator of STAT3, been evaluated.
  • Here, we demonstrate that activated STAT3 (pSTAT3) and activated JAK3 (pJAK3) are expressed constitutively in two colon cancer cell lines, SW480 and HT29.
  • The blockade of JAK3/STAT3 signaling significantly decreased viability of colon cancer cells due to apoptosis and cell-cycle arrest through down-regulation of Bcl-2, Bcl-X(L), Mcl-1, and cyclin D2 and up-regulation of p21(waf1/cip1) and p27(kip1).
  • We also examined histological sections from 22 tumors from patients with stage II or stage IV colon cancer and found STAT3, JAK3, and their activated forms to be frequently expressed.
  • Furthermore, quantitative reverse transcriptase-polymerase chain reaction identified JAK3 mRNA in colon cancer cell lines and primary tumors.
  • Our findings illustrate the biological importance of JAK3/STAT3 activation in the oncogenesis of colon cancer and provide novel evidence that JAK3 is expressed and contributes to STAT3 activation in this malignant neoplasm.
  • [MeSH-minor] Aged. Cell Line, Tumor. Cell Survival / drug effects. Cyclin D2. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclins / metabolism. Enzyme Activation. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic / drug effects. HT29 Cells. Humans. Immunohistochemistry. Janus Kinase 3. Male. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / drug effects. Tyrphostins / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Med. 1999 Nov;5(11):711-20 [10656873.001]
  • [Cites] Leukemia. 2001 May;15(5):787-93 [11368440.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 Jul 6;19(29):3290-8 [10918585.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):24096-105 [10918073.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):825-32 [10965024.001]
  • [Cites] Cell Signal. 2000 Aug;12(8):525-35 [11027945.001]
  • [Cites] Eur J Biochem. 2000 Nov;267(21):6435-42 [11029587.001]
  • [Cites] Trends Biochem Sci. 2000 Oct;25(10):496-502 [11050435.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5419-27 [11114718.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2008-15 [11264165.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2026-32 [11391581.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] Blood. 2001 Aug 1;98(3):762-70 [11468177.001]
  • [Cites] Trends Mol Med. 2001 Dec;7(12):542-7 [11733216.001]
  • [Cites] Cell Signal. 2002 Apr;14(4):317-25 [11858939.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3334-58 [12032773.001]
  • [Cites] Gene. 2002 Feb 20;285(1-2):1-24 [12039028.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4997-5001 [12118379.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4390-7 [12154045.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Sep;27(3):306-13 [12204892.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36167-73 [12147685.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7797-807 [12420216.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6659-66 [12438264.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2316-24 [12441269.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2990-6 [12438313.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2940-54 [12480704.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):461-9 [12748308.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31574-83 [12771142.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5399-407 [12934099.001]
  • [Cites] J Cell Physiol. 2003 Nov;197(2):157-68 [14502555.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4802-10 [14581351.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8271-82 [14614451.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50402-11 [14523021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8705-9 [7568001.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):25028-36 [7559633.001]
  • [Cites] J Biol Chem. 1995 Dec 22;270(51):30829-36 [8530527.001]
  • [Cites] J Immunol. 1996 Apr 15;156(8):2972-8 [8609418.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):13976-80 [8662778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6764-9 [9192639.001]
  • [Cites] Clin Exp Immunol. 1998 Jan;111(1):211-8 [9472684.001]
  • [Cites] Circulation. 1998 Jul 28;98(4):346-52 [9711940.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1103-10 [9815900.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3897-904 [10201908.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Transplant Proc. 2001 Feb-Mar;33(1-2):95 [11266723.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):327-34 [11310826.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9102-5 [10734041.001]
  • (PMID = 16192633.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / CDKN1A protein, human; 0 / Cyclin D2; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Enzyme Inhibitors; 0 / JAK3 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinase 3
  • [Other-IDs] NLM/ PMC1603671
  •  go-up   go-down


3. Are C, Iacovitti S, Prete F, Crafa FM: Feasibility of laparoscopic portal vein ligation prior to major hepatectomy. HPB (Oxford); 2008;10(4):229-33
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A subset of patients undergo laparoscopic intervention prior to PVE for staging purposes or to address the primary in Stage IV colon cancer.
  • RESULTS: A total of nine patients underwent LPVL as part of a two stage procedure in preparation for subsequent major hepatectomy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2007 Nov;94(11):1386-94 [17583900.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):297-303 [18060468.001]
  • [Cites] Br J Surg. 2006 May;93(5):587-92 [16523448.001]
  • [Cites] Arch Surg. 2005 Aug;140(8):727-34 [16103281.001]
  • [Cites] Radiology. 2005 Feb;234(2):625-30 [15591428.001]
  • [Cites] Arch Surg. 2004 Dec;139(12):1326-30 [15611458.001]
  • [Cites] Br J Surg. 1999 Jun;86(6):784-8 [10383579.001]
  • [Cites] J Hepatol. 1997 Nov;27(5):871-80 [9382975.001]
  • [Cites] Surgery. 1997 Feb;121(2):135-41 [9037224.001]
  • [Cites] Hepatology. 1996 Dec;24(6):1386-91 [8938166.001]
  • [Cites] Surgery. 1994 Jun;115(6):674-7 [8197557.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):109-15 [8383379.001]
  • [Cites] World J Surg. 1986 Oct;10(5):803-8 [3022488.001]
  • [Cites] Surgery. 1990 May;107(5):521-7 [2333592.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):413-8 [15086171.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] Hepatology. 2001 Aug;34(2):267-72 [11481611.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):480-6 [10749607.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):855-9 [17380479.001]
  • (PMID = 18806869.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2518294
  • [Keywords] NOTNLM ; future liver remnant / laparoscopy / portal vein ligation
  •  go-up   go-down


Advertisement
4. Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI: Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics; 2009 Jan-Feb;6(1):19-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
  • BACKGROUND: Human cancer is characterized by high heterogeneity in gene expression, varieties of differentiation phenotypes and tumor-host interrelations.
  • Growing evidence suggests that tumor-initiating, or cancer stem cells (CSCs), may also represent a heterogeneous population.
  • The present study was undertaken to isolate and characterize the different phenotypic subpopulations of metastatic colon cancer and to develop a working colon CSC model for obtaining highly tumorigenic and clonogenic cells in sufficient numbers.
  • RESULTS: The metastatic colon cancer HCT116 cell line, which expressed a majority of known CSC markers, closely resembling the patterns of expression in exfoliated peritoneal cells from several metastatic colon cancer patients, was selected as a reference material.
  • Simultaneous analysis of 84 stem cell- and metastasis-related genes with corresponding PCR arrays identified genes differentially expressed in several colon CSC phenotypic populations versus bulk tumor cells, and in relation to each other.
  • Genomic analysis of several candidate CSC phenotypic populations may contribute to the identification of novel targets for colon cancer stem cell-targeted drug development and treatment.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451087.001).
  • [ISSN] 1109-6535
  • [Journal-full-title] Cancer genomics & proteomics
  • [ISO-abbreviation] Cancer Genomics Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


5. Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M: Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol; 2010 Dec 21;16(47):5965-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.
  • AIM: To develop a multiplex reverse transcription polymerase chain reaction (RT-PCR) method detecting circulating tumor cells in the peripheral blood of colorectal cancer (CRC) patients.
  • The analysis involved determining the detection rates of CEA, CK20 and EGFR transcripts vs disease stage and overall survival.
  • The increasing number of positive detections for CEA, CK20 and EGFR transcripts in each blood sample was positively correlated with Astler-Coller disease stage (P < 0.001) and preoperative serum levels of CEA (P = 0.029) in CRC patients.
  • CONCLUSION: These data suggest that multiplex RT-PCR assay can provide useful information concerning disease stage and overall survival of CRC patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Apr;29(4):422-8 [15770378.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2329-34 [17914651.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4158-63 [10632355.001]
  • [Cites] Lancet. 2000 Jan 29;355(9201):395-9 [10665570.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1439-44 [10778975.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):58-65 [10862196.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94 [10959054.001]
  • [Cites] Clin Exp Metastasis. 1999;17(10):823-30 [11089880.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):65-73 [11121864.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2523-32 [11289125.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):577-83 [11297251.001]
  • [Cites] Exp Mol Med. 2001 Mar 31;33(1):8-14 [11322488.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):141-6 [11459287.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3951-9 [11579116.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8845-50 [11751407.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4080-5 [11751505.001]
  • [Cites] Gut. 2002 Apr;50(4):530-4 [11889075.001]
  • [Cites] Mol Pathol. 2002 Jun;55(3):156-63 [12032226.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):217-22 [12469172.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):425-30 [12527944.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):3135-42 [16080577.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1199-202 [16211285.001]
  • [Cites] J Mol Diagn. 2005 Nov;7(5):631-7 [16258162.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):297-306 [16391782.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):105-12 [16436641.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):385-9 [17058136.001]
  • [Cites] Clin Chem Lab Med. 2006;44(12):1403-9 [17163814.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1092-8 [17200912.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2406-13 [17406027.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1188-203 [17436048.001]
  • [Cites] Clin Chem Lab Med. 2007;45(11):1488-94 [17924845.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):1040-6 [18043108.001]
  • [Cites] J Surg Oncol. 2007 Dec 15;96(8):693-703 [18081153.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):267-79 [18262345.001]
  • [Cites] Cell Oncol. 2008;30(6):463-71 [18936523.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):770-6 [18845519.001]
  • [Cites] Clin Chem Lab Med. 2009;47(1):1-11 [19055471.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):3945-60 [19192655.001]
  • [Cites] Mol Med. 2009 Mar-Apr;15(3-4):101-14 [19081770.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):272-9 [19103472.001]
  • [Cites] Cancer. 2010 Jun 15;116(12):2913-21 [20336782.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2678-82 [12855647.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):989-95 [12905553.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):324-30; discussion 330-1 [14501498.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):587-91 [14735340.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Dis Colon Rectum. 1980 Apr;23(3):141-4 [7379666.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):66-73 [3510056.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Blood. 1997 Jan 1;89(1):337-44 [8978310.001]
  • [Cites] Exp Hematol. 1997 Jan;25(1):57-65 [8989908.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):343-8 [9516921.001]
  • [Cites] Int J Cancer. 1998 Jun 19;79(3):288-93 [9645353.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3037-43 [9865918.001]
  • [Cites] J Mol Med (Berl). 2004 Nov;82(11):768-74 [15490093.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):436-8 [15637763.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):495-505 [15679047.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):137-46 [15459772.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(2):155-96 [15941083.001]
  • (PMID = 21157973.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3007112
  •  go-up   go-down


6. Labianca R, La Verde N, Garassino MC: Development and clinical indications of cetuximab. Int J Biol Markers; 2007 S4 - Jan-Mar;22(4):40-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The EGFR signaling pathways regulate cell differentiation, proliferation, migration, angiogenesis and apoptosis, all of which become deregulated in cancer cells.
  • EGFR is an important target for cancer therapy and many studies have demonstrated that cetuximab is active in several types of cancer, particularly colorectal and head and neck cancer.
  • On the basis of a pivotal European randomized study (the BOND study) and of 2 clinical studies conducted in the USA, cetuximab has been approved in combination with irinotecan for patients affected by EGFR-expressing metastatic colon cancer after failure with irinotecan.
  • There have only been a few small phase II trials on first-line treatment in metastatic colorectal cancer, but the results suggest promising activity of cetuximab together with irinotecan or oxaliplatin.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207113.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, Cherqui D, Tran Van Nhieu J: Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol; 2008 Dec;15(12):3440-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy has also an effect on primary tumor in colon carcinoma.
  • METHODS: Between 2000 and 2006, 38 patients with stage IV colon cancer underwent resection of the primary, after chemotherapy (CT group, n = 16) or without preoperative CT (control group, n = 22).
  • CONCLUSION: CT induces major histological response in 70% of colon cancers.
  • These results support a policy of initial CT management for stage IV colon cancer and may warrant future studies of neoadjuvant CT in locally advanced colon carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / drug therapy. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850249.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Uña E: Atypical presentation of acute neurotoxicity secondary to oxaliplatin. J Oncol Pharm Pract; 2010 Dec;16(4):280-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old female diagnosed with stage IV colon cancer, underwent palliative treatment with combination of oxaliplatin (130 mg/m( 2) on day 1), capecitabine (1.250 mg/m(2) bid on days 1 to 14 every 3 weeks), and bevacizumab.

  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20015928.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Shoji H, Kuroki M, Hiramoto K, Matsumura Y, Miura A, Kikuchi Y, Hirakawa H: [A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1583-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
  • We report a rare case of metastatic colorectal cancer who suffered from hyperammonemic encephalopathy induced by 5- FU and was continuously treated with FOLFOX therapy.
  • A 50-year-old man with ileus was diagnosed with ascending colon cancer Stage IV, and a right hemicolectomy was performed.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716892.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acids, Branched-Chain; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


10. Segelman J, Singnomklao T, Hellborg H, Martling A: Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis; 2009 Sep;11(7):768-74
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer.
  • OBJECTIVE: At diagnosis, 14-27% of patients with colorectal cancer (CRC) have distant metastases (stage IV) and a poor prognosis.
  • The aim of this study was to evaluate the effects of development and implementation of MDT assessment and treatment in patients with stage IV colon cancer (CC) and rectal cancer (RC) in a large population.
  • METHOD: All 1449 patients who had stage IV CRC at the time of diagnosis and were registered in the regional quality registry of Stockholm from 1995 to 2004 were included.
  • RESULTS: In total, 1000 patients with CC and 449 patients with RC had stage IV disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662241.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Hofmann LJ, Lee S, Waddell B, Davis KG: Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum; 2010 Jan;53(1):9-15
MedlinePlus Health Information. consumer health - African American Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system.
  • PURPOSE: The increase in mortality noted in African Americans with colon cancer is attributed to advanced stage at presentation and disparities in treatment received.
  • The aim of this study was to assess the influence of race on the treatments and survival of colon cancer patients in an equal-access healthcare system.
  • METHODS: This retrospective cohort study included African American and white patients with colon cancer treated at Department of Defense facilities.
  • Disease stage, surgery performed, chemotherapy used, and overall survival were evaluated.
  • RESULTS: Of the 6958 colon cancer patients identified, 1115 were African American.
  • African Americans presented more frequently with stage IV disease, 23% vs 17% for whites (P < .001).
  • There was no difference in the use of systemic chemotherapy for stage III colon cancer (73.5% for African Americans vs 72.2% for whites; chi2, P > .05) or stage IV colon cancer (56.3% for African Americans vs 54.4% for whites; chi2, P > .05).
  • After adjusting for gender, age, tumor grade, and stage, African American race was not a risk factor for survival in Cox proportional hazard analysis (hazard ratio, 0.981; 95% confidence interval, 0.888-1.084).
  • African American patients undergo surgery and chemotherapy is administered at rates equal to whites for all stages of colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010344.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ladino M, Guardiola VD, Paniagua M: Mirtazapine-induced hyponatremia in an elderly hospice patient. J Palliat Med; 2006 Apr;9(2):258-60
Hazardous Substances Data Bank. MIANSERIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 72-year-old Latino male with stage IV colon cancer entered into hospice care and was treated for major depressive disorder with mirtazapine.

  • MedlinePlus Health Information. consumer health - Hospice Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629552.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 250PJI13LM / Mianserin; A051Q2099Q / mirtazapine
  •  go-up   go-down


13. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). J Clin Oncol; 2009 May 20;27(15_suppl):e15114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL).
  • : e15114 Background: In a previous study, IFL was used in patients (pt) with untreated metastatic colon cancer and a median overall survival (MOS) of 31 months (m).
  • The estimated median time to progression was 13 m with corresponding lower 95% confidence bound of 8.4 m.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Correale P, Tagliaferri P, Del Vecchio MT, Remondo C, Migali C, Tsang KY, Rotundo MS, Fulfaro F, Tassone P, Francini G: Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):3045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients.
  • : 3045 Background: GOLFIG is a novel chemoimmunotherapy regimen, combining gemcitabine, oxaliplatin, 5-FU/FA with immunoadjuvant GM-CSF and aldesleukine, which resulted safe and very active in colon cancer patients.
  • METHODS: An immunohistochemistry study was carried out to quantify the infiltration of Treg (FoxP3+) lymphocytes in tumor samples of 41 colon cancer patients who received FOLFOX-4 chemotherapy or GOLFIG chemo-immunotherapy as enrolled in the ongoing phase III GOLFIG-2 trial.
  • CONCLUSIONS: Our results suggest that GOLFIG chemoimmunotherapy is highly effective in colon carcinoma patients with high FoxP3+ infiltration score and that Treg-tumor infiltration score may be a favorable prognostic marker in colon cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961976.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sobhani I, Roudot-Thoraval F, Mesli F, Landi B, Aparicio T, Louvet C, DesGuetz G, Mitry E: Outcome of colon cancer patients with synchronous metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of colon cancer patients with synchronous metastases.
  • : 4029 Background: Metastatic colon cancer patients may undergo chemotherapy without colon surgery.
  • METHODS: Consecutive patients [N=228, mean age (sd) 64 (12) yrs, median follow-up 20 mths;84 females] treated in 6 teaching hospitals received chemotherapy for metastatic colonic cancer, either as the first step, or after surgery.
  • RESULTS: 105 patients with colon cancer and synchronous metastatsis underwent colon surgery prior to chemotherapy (68 males, mean age 64 yrs) when 123 patients were treated first by chemotherapy ± biotherapy (76 males, mean age 63 yrs).
  • CONCLUSIONS: Colon surgery before chemotherapy plus bevacizumab appears to be the more appropriate choice, and associated with longer PFS, especially for those patients with well differentiated tumours and synchronous liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vukelja S, Richards D, Campos LT, Bedell C, Hagenstad C, Hyman W, Letzer J, Gardner L, Sportelli P, Nemunaitis J: Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.
  • In a phase I solid tumor trial, Peri was safely combined with capecitabine (Cap) and demonstrated interesting activity in patients (pts) with metastatic colorectal cancer (mCRC), with one patient progression-free for 49 weeks (wks).
  • Primary outcome analyses included median time to progression (TTP) and response rate (CR+PR).
  • CONCLUSIONS: Perifosine in combination with capecitabine was well tolerated, clinically active and more than doubled median TTP over capecitabine alone in pts with advanced, metastatic CRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961645.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Metges J, Gamelin E, Faroux R, Klein V, Ganem G, Douillard J, Stampfli C, Corbinais S, Riche C, Grude F: AVASTERB OUEST: A prospective cohort study of unresectable metastatic colon cancer treated successively by FOLFIRI bevacizumab and cetuximab irinotecan. J Clin Oncol; 2009 May 20;27(15_suppl):e15103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AVASTERB OUEST: A prospective cohort study of unresectable metastatic colon cancer treated successively by FOLFIRI bevacizumab and cetuximab irinotecan.
  • : e15103 Background: Bevacizumab and cetuximab regimen are approuved since 2005 in Europe for Metastatic Colorectal Cancer Patients (MCCP).
  • METHODS: Since 2003, in west of France, (Bretagne-Pays de Loire),a network called OMIT(Observatoire des Médicaments et Innovations Thérapeutiques) directed by Regional Health Agencies has been created.
  • In order to have a large follow up, the 35 first patients of the cohort were studied in this abstract.Age, sex, response rate to the different regimens,secondary metastatic lesion resection, time to progression to the different regimens, follow up and overall survival are the criterias studied.
  • RESULTS: Median age 60 years (49-83), Males : 60%, colon 71%,rectum: 17%, colorectal jonction :12%.Response rate(OR+SD)with Folfiri Bevacizumab : 45.7%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bengala C, Bettelli S, Fontana A, Bertolini F, Sartori G, Malavasi N, Losi L, Del Giovane C, Luppi G, Conte P: EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy.
  • : e15055 Background: Cetuximab and panitumumab have proven to be effective in metastatic colon cancer (mCRC).
  • Twenty- one pts were treated in 1<sup>st</sup>-2<sup>nd</sup> line and 42 pts in 3<sup>rd</sup>-4<sup>th</sup> line.
  • So far EGFR GCN is available on 55 pts, KRAS and BRAF on 63 pts, PTEN in primary tumor (PT) on 36 pts and in metastatic (MTS) site on 24 pts, AKT on 19 pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Takahashi S, Nagai K, Saito N, Konishi M, Nakagohri T, Gotohda N, Nishimura M, Yoshida J, Kinoshita T: Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma. Jpn J Clin Oncol; 2007 Mar;37(3):186-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Resections are effective for some patients with both hepatic and pulmonary metastases of colorectal cancer, but the best selection criteria for the resections and effective treatment for recurrence after the resections have not been determined.
  • METHODS: A retrospective analysis was performed for 30 consecutive patients who received aggressive multiple resections for both hepatic and pulmonary metastases of colorectal cancer.
  • Multivariate analyses revealed that primary colon cancer, stage IV in TNM classification and maximum size of hepatic tumor >3 cm at initial hepatectomy were poor prognostic factors, but several long-term survivors were observed even among patients with those factors.
  • CONCLUSIONS: Multiple resections for hepatic and pulmonary metastases of colorectal cancer are safe and effective.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Hepatectomy. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Pneumonectomy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472970.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


20. Zanon C, Bortolini M, Chiappino I, Simone P, Bruno F, Gaglia P, Airoldi M, Deriu L, Mashiah A: Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg; 2006 Nov;30(11):2025-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.
  • The multicentric France EVOCAPE 1 study demonstrated that the median overall survival of patients with colon peritoneal carcinomatosis subjected to conventional surgical and/or chemotherapeutic treatment was 5.2 months.
  • Historically, mitomycin C is the drug of choice in the treatment of intraperitoneal carcinomatosis from colon cancer.
  • METHODS: Twenty-five patients affected by stage IV colon cancer with only peritoneal involvement and a prior completion of at least a partial first cycle of systemic chemotherapeutic and/or surgical treatment (24 patients) were enrolled.
  • CONCLUSIONS: In referral centers CHPP after optimal surgical debulking is a safe procedure for peritoneal carcinomatosis from colonic cancer.
  • These results, as in other published phase II studies, justify future randomized trials to assess definitively the role of CHPP in the treatment of locally advanced colon neoplasms in western countries.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):26-33 [12511145.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):694-8 [11821450.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • [Cites] Ann Surg Oncol. 1996 Jan;3(1):44-50 [8770301.001]
  • [Cites] Biomed Pharmacother. 1995;49(9):429-30 [8746079.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(1):6-12 [8996534.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Int J Surg Investig. 2000;1(5):431-9 [11341599.001]
  • [Cites] Am Surg. 2000 Jun;66(6):561-8 [10888132.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):147-52 [15698730.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):663-8 [11078613.001]
  • [Cites] Cancer Treat Res. 1996;81:51-61 [8834575.001]
  • [Cites] Ann Chir. 2000 Sep;125(7):631-42 [11051692.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S15-25 [10357554.001]
  • [Cites] Drugs. 1995 Jan;49(1):11-9 [7705211.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Life Sci. 1996;58(7):535-43 [8632706.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2512-9 [10861427.001]
  • [Cites] Int J Hyperthermia. 2001 Sep-Oct;17(5):456-64 [11587082.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] Oncologist. 2005 Feb;10(2):112-22 [15709213.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1006-15 [10931042.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):286-90 [11373107.001]
  • (PMID = 17058031.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Renouf D, Kennecke H, Gill S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):386-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in chemotherapy utilization for colorectal cancer.
  • BACKGROUND: Since 1990, significant advances have occurred in the adjuvant and metastatic treatment of colorectal cancer (CRC).
  • In this study, treatment patterns of patients referred to the British Columbia Cancer Agency (BCCA) with early-stage colon cancer and metastatic CRC between 1990 and 2004 are described.
  • PATIENTS AND METHODS: This study included patients with stage II or III colon cancer or stage IV CRC at presentation referred to the BCCA during a 1-year period for 3 time cohorts: 1990, 2000, and 2004.
  • RESULTS: A total of 1421 patients were included: stage II/III, n = 915; stage IV, n = 506.
  • The proportion of patients with stage II disease treated with adjuvant CT dramatically increased (1990: 4%; 2000: 26%; 2004: 30%; P < .001).
  • [MeSH-minor] Aged. British Columbia / epidemiology. Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036691.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Hiraki M, Yakushiji H, Hashiguchi K, Harada S: [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1055-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
  • Combined chemotherapy consisting of oral TS-1 and low-dose CPT-11 by hepatic arterial infusion is suggested to be a new effective treatment for multiple liver metastases from colorectal cancer.
  • A 53-year-old man was diagnosed with multiple hepatic metastases from advanced colon cancer (Stage IV).
  • The patient underwent partial resection of the colon and catheter insertion into hepatic artery for arterial infusion in November 2003.
  • In spite of the reduction of metastatic liver tumors after 2 cycles of the chemotherapy, a metastatic pleural tumor appeared.

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044973.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B: A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer; 2009 Jan;8(1):43-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of the MTHFR gene polymorphism C677T in colorectal cancer.
  • PURPOSE: The aim of this study was to examine the clinical significance of the methylenetetrahydrofolate reductase (MTHFR) gene polymorphism C677T in colorectal cancer (CRC).
  • The hypothesis was that the genotype could affect the risk of cancer development and the results of cancer treatment.
  • RESULTS: No genotype was associated with an increased risk of CRC or higher cancer stage.
  • In stage III colon cancer, the patients with CT/TT genotype had a poorer prognosis than those with the CC genotype.
  • Though the genotype-associated side effect risks remained in stage IV, the effect on survival was not significant (P < .1).
  • CONCLUSION: The MTHFR polymorphism C677T does, in our material, not affect the risk of CRC; however, it can affect the sensitivity to chemotherapy and the risk of side-effects and therefore survival in stage III and possibly stage IV colon cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Polymorphism, Genetic. Prognosis. Proportional Hazards Models. Retrospective Studies. Statistics, Nonparametric. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203896.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


24. Ahmadi A, Mohagheghi M, Karimi M, Seyed Ali Golestanha, Naseri M: Anticancer effects of HESA-A in patients with metastatic colon cancer. Integr Cancer Ther; 2009 Mar;8(1):71-4
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer effects of HESA-A in patients with metastatic colon cancer.
  • The aim of this study was to investigate the therapeutic effects of HESA-A in patients with metastatic colon cancer.
  • METHODS: Fifty consecutive patients with end-stage colon cancer and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied.
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. Female. Humans. Iran / epidemiology. Karnofsky Performance Status. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147644.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / HESA-A preparation; 0 / Plant Preparations
  •  go-up   go-down


25. Wakahara T, Tsukamoto T, Kitamura S, Watanabe A, Tsujimura T, Nakamura Y, Toyokawa A, Onishi N, Hamabe Y, Mukai H, Teramura K: Metastatic colon cancer from intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg; 2005;12(5):415-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer from intrahepatic cholangiocarcinoma.
  • A 62-year-old man had been followed because of an elevated serum level of carcinoembryonic antigen without the detection of any cancer lesions.
  • However, there was a sudden increase in the serum level of carcinoembryonic antigen, and abdominal imagings showed a hepatic tumor with peripheral intrahepatic bile duct dilatation, and a submucosal tumor at the sigmoid colon with intact mucosa.
  • Histopathological findings showed that the hepatic tumor had perineural invasion, suggesting an intrahepatic cholangiocarcinoma, and that the colon tumor infiltrated the submucosa, while its mucosa was intact.
  • These findings suggested intrahepatic cholangiocarcinoma with metastatic sigmoid colon cancer.

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258812.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


26. Gmeiner WH, Hellmann GM, Shen P: Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Oncol Rep; 2008 Jan;19(1):245-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue-dependent and -independent gene expression changes in metastatic colon cancer.
  • The goal of this study was to identify systematic alterations in key cell signaling and metabolic pathways that occur during colon cancer carcinogenesis and metastasis.
  • Gene expression levels for primary colon samples were compared to a normal colon while metastatic tissues were compared to the primary colon.
  • Primary colon samples displayed high positive z-scores (indicating a gene ontology term that occurs more frequently than expected) for genes involved in Wnt-signaling (4.11), nitrogen metabolism (7.30) and inositol phosphate metabolism (2.47).
  • Metastatic tissue from the liver and omentum, but not the lung, displayed a decreased expression of genes important for oxidative phosphorylation.
  • The metastatic tissue from all sites displayed a substantially decreased expression for genes involved in butanoate and propanoate metabolism and valine, leucine and isoleucine degradation.
  • These expression level changes complement the spectrum of mutations that characterize the progression of colorectal cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097602.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA102532; United States / NCI NIH HHS / CA / P30 CA12197
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Wnt Proteins; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


27. von Wichert G, Krndija D, Schmid H, von Wichert G, Haerter G, Adler G, Seufferlein T, Sheetz MP: Focal adhesion kinase mediates defects in the force-dependent reinforcement of initial integrin-cytoskeleton linkages in metastatic colon cancer cell lines. Eur J Cell Biol; 2008 Jan;87(1):1-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal adhesion kinase mediates defects in the force-dependent reinforcement of initial integrin-cytoskeleton linkages in metastatic colon cancer cell lines.
  • Here, we show that metastatic human colon cancer cell lines display altered matrix interaction.
  • Interaction of colon cancer cells with collagen I depends on integrins (mainly alpha(1)/beta(1)) but metastatic cells display delayed spreading and reduced extension of lamellipodia.
  • However, adhesion to pliable surfaces is ameliorated in metastatic variants.
  • In addition, consistent with defective strengthening of integrin-cytoskeleton linkages, metastatic cell lines show reduced random motility.
  • Taken together these data suggest that constitutive activation of FAK causes defects in spreading, reinforcement of integrin-cytoskeleton linkages and migration and at the same time could ameliorate the adhesion of metastatic cells to suboptimal surfaces.
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Line, Tumor. Enzyme Activation / drug effects. Humans. Neoplasm Metastasis. RNA Interference. RNA, Small Interfering / pharmacology. Stress, Mechanical

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904248.001).
  • [ISSN] 0171-9335
  • [Journal-full-title] European journal of cell biology
  • [ISO-abbreviation] Eur. J. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Integrin alpha1beta1; 0 / RNA, Small Interfering; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


28. Ryan DP: Nonsurgical approaches to colorectal cancer. Oncologist; 2006 Oct;11(9):999-1002
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical approaches to colorectal cancer.
  • It is time to challenge the current orthodoxy that frowns upon surgical and nonsurgical methods of tumor reduction for patients with metastatic colon cancer.
  • Although the studies conducted with radiofrequency ablation, chemoembolization, and radiation therapy in patients with metastatic colon cancer have tended to be small and may have been subject to selection bias, they have produced survival data that require careful consideration.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030641.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine
  • [Number-of-references] 16
  •  go-up   go-down


29. Gamblin TC, Santos RS, Baratz M, Landreneau RJ: Metastatic colon cancer to the hand. Am Surg; 2006 Jan;72(1):98-100
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer to the hand.
  • A 72-year-old male presented with a painful index finger 18 months after sigmoid colon resection for T2 N1 adenocarcinoma.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494196.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Iida T, Shiba H, Misawa T, Ohashi T, Eto Y, Yanaga K: Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. Surgery; 2010 Nov;148(5):925-35
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand.
  • BACKGROUND: Colon cancer is one of the most common cancers worldwide, and liver metastasis is a poor prognostic factor for all types of digestive cancers, including colon cancer.
  • We studied CD40 ligand (CD40L)-mediated immunogene therapy for metastatic liver cancer in rats.
  • METHODS: We studied whether in vitro infection of a rat colon cancer cell line (RCN9) with an adenoviral-vector that expresses the CD40L (AxCAmCD40L) induced CD40L expression.
  • CONCLUSION: These observations suggest that CD40L-mediated immunogene therapy for metastatic colon cancer in the liver and lungs is effective and is mediated by the activation of both the cellular and humoral immune systems.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Mosby, Inc.
  • (PMID = 20378141.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 147205-72-9 / CD40 Ligand
  •  go-up   go-down


31. Plesec TP, Hunt JL: KRAS mutation testing in colorectal cancer. Adv Anat Pathol; 2009 Jul;16(4):196-203
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation testing in colorectal cancer.
  • In the US, colorectal cancer is the third leading cause of cancer-related death.
  • Approximately 20% of patients present with metastatic disease, and an additional 30% to 40% develop metastasis during the course of their disease.
  • Patients with metastatic colon cancer have a 5-year survival rate of only 11%.
  • Although surgery is the mainstay of treatment for early stage colon cancer, adjuvant treatment is usually used in patients advanced stage disease.
  • In particular, epidermal growth factor receptor (EGFR) inhibitor therapies have emerged as effective treatments in a subset of patients with metastatic colorectal carcinoma.
  • Two anti-EGFR biologics, cetuximab and panitumumab, have been approved by the Food and Drug Administrations for the treatment of refractory metastatic colorectal carcinoma.
  • Because of this compelling data, the National Comprehensive Cancer Network and the American Society of Clinical Oncology have recommended determination of KRAS mutation status in all patients with metastatic colorectal cancer who are candidates for anti-EGFR therapy.
  • Herein, the authors present an up-to-date review of the biologic, clinical, and laboratory aspects of KRAS mutation testing in colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546608.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Codon; 0 / KRAS protein, human; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 78
  •  go-up   go-down


32. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD: Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer; 2009 Jul 15;125(2):463-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.
  • Despite recent therapeutic advances, the response rates to chemotherapy for patients with metastatic colon cancer remain at approximately 50% with the fluoropyrimidine, 5-fluorouracil (5-FU), continuing to serve as the foundation chemotherapeutic agent for the treatment of this disease.
  • In this study, we demonstrate that the histone deacetylase inhibitors (HDACi) vorinostat and LBH589 significantly downregulate TS gene expression in a panel of colon cancer cell lines.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19384949.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Pyrimidines; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


33. Huerta S, Li HC: Bevacizumab-associated hypertension: etiology, incidence, and management. Anticancer Drugs; 2009 May;20 Spec No 2:S22-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor signaling pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352106.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Wilkinson N, Scott-Conner CE: Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am; 2008 Mar;37(1):253-67, ix
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer (CRC) remains the second leading cause of cancer mortality among men, and the third leading cause among women.
  • Worldwide, CRC is the fourth most common cancer with approximately 1 million new cases annually.
  • Locally advanced rectal cancer, node-positive colon cancer, and metastatic disease still compose a significant proportion of colon and rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313549.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


35. Siddiqui A, Khandelwal N, Anthony T, Huerta S: Colonic stent versus surgery for the management of acute malignant colonic obstruction: a decision analysis. Aliment Pharmacol Ther; 2007 Nov 15;26(10):1379-86
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic stent versus surgery for the management of acute malignant colonic obstruction: a decision analysis.
  • AIM: To compare the clinical outcomes and cost-effectiveness of endoscopic self-expanding metal stent (SEMS) vs. surgery for emergent management of acute malignant colonic obstruction in patients with metastatic colorectal cancer over a 6-month period.
  • METHODS: Decision analysis was used to calculate the cost-effectiveness and success of two competing strategies in a hypothetical patient with metastatic colon cancer presenting with acute, malignant colonic obstruction: (i) emergent colonic stent (SEMS cohort);.
  • CONCLUSION: Colonic stent insertion is more effective and less costly than surgery for the management of colonic obstruction in patients with metastatic colon cancer.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Aliment Pharmacol Ther. 2008 Mar 1;27(5):448 [18226115.001]
  • (PMID = 17848183.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


36. Reddy N, Yu J, Fakih MG: Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer; 2007 Jan;6(5):362-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy.
  • PURPOSE: Patients aged > or = 70 years with colon cancer benefit from chemotherapy, with no major added toxicities compared with a younger population.
  • However, the safety and efficacy of chemotherapy or chemoradiation therapy in octogenarians and nonagenarians with colorectal cancer (CRC) has not been previously reported.
  • PATIENTS AND METHODS: We conducted a retrospective study of the safety and efficacy of chemotherapy or chemoradiation therapy in patients with CRC treated between January 2002 and June 2006 at Roswell Park Cancer Institute.
  • RESULTS: Thirty-three patients were identified, 24 of whom had colon cancer and 9 of whom had rectal cancer.
  • Twenty-two patients with metastatic colon cancer and 8 patients with rectal cancer were evaluable for toxicity.
  • A high rate of severe diarrhea (46%) and treatment-related hospitalizations (73%) were noted among patients with metastatic colon cancer.
  • The median overall survival among the metastatic colon cancer cohort was 20.6 months (95% confidence interval, 11.1-26.4 months).
  • Among the patients with rectal cancer, 5 had locally advanced disease and were treated with chemoradiation therapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311701.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Pfeiffer P, Jensen BV: [Drug therapy of patients with metastatic colorectal cancer]. Ugeskr Laeger; 2005 Nov 7;167(45):4261-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug therapy of patients with metastatic colorectal cancer].
  • [Transliterated title] Medicinsk behandling af patienter med metastatisk kolorektal cancer.
  • In less than a decade, metastatic cancer in the colon or rectum has changed from being primarily a surgically palliated disease to one in which there have been increasing successes with combination chemotherapy and molecular targeted therapy.
  • Instead of being a more or less acute life-threatening disease, metastatic colorectal cancer may exist as a chronic condition for years.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277924.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 10
  •  go-up   go-down


38. Janney LM, Waterbury NV: Capecitabine-warfarin interaction. Ann Pharmacother; 2005 Sep;39(9):1546-51
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 59-year-old man receiving chronic warfarin therapy for a mechanical mitral valve replacement was diagnosed with stage IV metastatic colon cancer.
  • He was started on capecitabine/irinotecan after his cancer progressed with fluorouracil/leucovorin and the FOLFOX 6 regimen (oxaliplatin, leucovorin, and continuous fluorouracil infusion).

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014372.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 5Q7ZVV76EI / Warfarin; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Fahy BN, D'Angelica M, DeMatteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, Gonen M, Jarnagin WR: Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol; 2009 Feb;16(2):361-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.
  • More effective chemotherapeutic agents have broadened the role of hepatic resection in the management of patients with synchronous hepatic metastases from colon cancer.
  • This study examines the management patterns and the role of hepatobiliary surgical evaluation in patients with synchronous stage IV colon cancer.
  • Patients with synchronous hepatic metastases from colon cancer evaluated and treated from 1/99 to 11/04 were analyzed retrospectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050976.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


40. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA, Lagasse E: A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res; 2008 Sep 1;68(17):6932-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A stochastic model for cancer stem cell origin in metastatic colon cancer.
  • Human cancers have been found to include transformed stem cells that may drive cancer progression to metastasis.
  • Here, we report that metastatic colon cancer contains clonally derived tumor cells with all of the critical properties expected of stem cells, including self-renewal and the ability to differentiate into mature colon cells.
  • Additionally, when injected into mice, these cells initiated tumors that closely resemble human cancer.
  • Karyotype analyses of parental and clonally derived tumor cells expressed many consistent (clonal) along with unique chromosomal aberrations, suggesting the presence of chromosomal instability in the cancer stem cells.
  • Thus, this new model for cancer origin and metastatic progression includes features of both the hierarchical model for cancerous stem cells and the stochastic model, driven by the observation of chromosomal instability.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1151-9 [16987840.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2055-64 [11493641.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):10-1 [12509774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Immunology. 1975 Jun;28(6):1135-48 [1079511.001]
  • [Cites] Methods Cell Biol. 1976;13:29-83 [177845.001]
  • [Cites] J Cell Biol. 1984 Mar;98(3):1026-32 [6699079.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1359-63 [2449944.001]
  • [Cites] Blood. 1989 Dec;74(8):2755-63 [2819245.001]
  • [Cites] Blood. 1991 Aug 15;78(4):945-52 [1678290.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2527-33 [1824250.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cell Res. 2007 Jan;17(1):3-14 [17179981.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):677-8; author reply 679-80 [17285131.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S71-80 [17382016.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):680-93 [17470736.001]
  • [Cites] Clin Colorectal Cancer. 2007 May;6(7):508-15 [17553199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Gene Ther. 2008 Jan;15(2):136-42 [17989699.001]
  • [Cites] J Pathol. 1993 Aug;170(4):441-50 [8410493.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1352-63 [7926500.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3653-9 [7524745.001]
  • [Cites] Differentiation. 1996 Jul;60(4):259-68 [8765056.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Semin Surg Oncol. 1996 Jul-Aug;12(4):219-52 [8829283.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):1137-41 [9378551.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):33-42 [15613286.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):11-24 [15784161.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Nat Med. 2006 Mar;12(3):296-300 [16520777.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):449-58 [16723991.001]
  • [Cites] Hepatology. 2001 Feb;33(2):363-78 [11172338.001]
  • (PMID = 18757407.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NIDCR NIH HHS / DE / R01 DE014729-05; None / None / / R01 DE014729-05; United States / NIDCR NIH HHS / DE / R01DE14729; United States / NIDCR NIH HHS / DE / R01 DE014729-04; United States / NCI NIH HHS / CA / CA047904-169019; United States / NCI NIH HHS / CA / P30 CA047904; United States / NCI NIH HHS / CA / CA047904-159019; United States / NCI NIH HHS / CA / P30CA047904; United States / NCI NIH HHS / CA / P30 CA047904-159019; United States / NIDCR NIH HHS / DE / R01 DE014729; United States / NCI NIH HHS / CA / P30 CA047904-169019; United States / NIDCR NIH HHS / DE / DE014729-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS57086; NLM/ PMC2562348
  •  go-up   go-down


41. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ: Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res; 2008 Apr 15;68(8):3037-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.
  • Sex steroid hormone receptors are expressed in the colon and interact with epidermal growth factor receptor (EGFR), a gene widely expressed in colonic tissue.
  • Increased EGFR expression is linked with poor prognosis in colon cancer.
  • These germ-line polymorphisms of EGFR were analyzed in genomic DNA from 318 metastatic colon cancer patients, 177 males and 141 females, collected from 1992 to 2003.
  • This study supports the role of functional EGFR polymorphisms as independent prognostic markers in metastatic colon cancer.
  • [MeSH-minor] Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Humans. Male. Neoplasm Metastasis. Recurrence. Retrospective Studies. Sex Characteristics. Survival Analysis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413774.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K24CA827540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


42. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E: Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol; 2007;46(8):1131-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
  • PATIENTS AND METHODS: Twenty-five adult patients scheduled to be treated with 12 courses of the oxaliplatin-based regimen, FOLFOX-4, for metastatic colon cancer participated in this study.
  • [MeSH-minor] Aged. Cohort Studies. Electrophysiology. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Motor Neurons / drug effects. Neoplasm Metastasis. Neurons, Afferent / drug effects. Severity of Illness Index

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851880.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


43. Toema BM: A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report. J Exp Ther Oncol; 2010;8(4):321-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report.
  • A Fifty three years old male with metastatic colon cancer to the liver started Panitumumab-Irinotecan palliative combination chemotherapy.
  • The aim of reporting this adverse event is to emphasize the recommendations of the National Comprehensive Cancer Network of discontinuing the use of Panitumumab-chemotherapy combination in metastatic colon cancer patients.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222364.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / panitumumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. Moritani S, Ichihara S, Seki Y, Kataoka M, Yokoi T: Pulmonary capillary hemangiomatosis incidentally detected in a lobectomy specimen for a metastatic colon cancer. Pathol Int; 2006 Jun;56(6):350-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary capillary hemangiomatosis incidentally detected in a lobectomy specimen for a metastatic colon cancer.
  • Presented herein is a case of pulmonary capillary hemangiomatosis incidentally detected in a surgically resected lung for a metastatic colon cancer.
  • The patient was a 60-year-old Japanese woman with a history of sigmoid colon cancer 3 years previously.
  • The patient had undergone a right lower lobectomy for a metastatic tumor in the hilar region and a thoracoscopic tumorectomy of the peripheral area of the left upper lobe.
  • The non-tumor area of right lower lobe showed multiple foci of capillary proliferation affecting alveolar walls, interlobular septa and pleura associated with patchy hemorrhage.
  • It is suggested this particular case is an incidentally detected clinically incipient stage of pulmonary capillary hemangiomatosis.
  • Passive congestion secondary to metastatic colon cancer in the hilar region may have contributed to the pathogenesis of this lesion.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704501.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


45. Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O: Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer; 2010;10:668
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.
  • However, its exact role in cancer is discussed controversially because both tumor suppressive and oncogenic effects have been described.
  • Here we followed-up on our previous observation that inhibition of Hsp90 may increase ATF3 expression and sought to determine the role of ATF3 in colon cancer.
  • METHODS: Regulation of ATF3 was determined in cancer cells using signaling inhibitors and a heat-shock protein-90 (Hsp90) antagonist.
  • Human HCT116 cancer cells were stably transfected with an ATF3-shRNA or a luciferase-shRNA expression plasmid and alterations in cell motility were assessed in migration assays.
  • The impact of ATF3 down-regulation on cancer growth and metastasis were investigated in a subcutaneous tumor model, a model of hepatic tumor growth and in a model of peritoneal carcinomatosis.
  • Human colon cancer tissues were analyzed for ATF3 expression.
  • RESULTS: The results show that therapeutic Hsp90 inhibition substantially up-regulates the expression of ATF3 in various cancer cells, including colon, gastric and pancreatic cancer.
  • RNAi mediated knock-down of ATF3 in HCT116 colon cancer cells significantly increased cancer cell migration in vitro.
  • Importantly, ATF3 expression was lower in human colon cancer specimens, as compared to corresponding normal surrounding tissues, suggesting that ATF3 may represent a down-regulated tumor suppressor in colon cancer.
  • CONCLUSION: In conclusion, ATF3 down-regulation in colon cancer promotes tumor growth and metastasis.
  • Considering that blocking Hsp90 induces ATF3 expression, Hsp90 inhibition may represent a valid strategy to treat metastatic colon cancer by up-regulating this anti-metastatic transcription factor.
  • [MeSH-minor] Animals. Cell Movement / drug effects. HCT116 Cells. Humans. Male. Mice. Mice, Nude. Neoplasm Invasiveness. RNA Interference. Time Factors. Transfection. Tumor Burden / drug effects. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):2868-78 [18025273.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6459-68 [17975158.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):250-62 [18772114.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):370-4 [18644253.001]
  • [Cites] Cell Cycle. 2009 Feb 15;8(4):518-26 [19197160.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2118-27 [17952119.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):833-6 [10965025.001]
  • [Cites] Pathobiology. 2000;68(4-5):227-31 [11279351.001]
  • [Cites] J Cell Physiol. 2001 Sep;188(3):352-8 [11473362.001]
  • [Cites] Oncol Res. 2001;12(8):343-6 [11589305.001]
  • [Cites] J Cell Sci. 2002 Jul 15;115(Pt 14):2809-16 [12082142.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1182-7 [12402160.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):213-7 [12676580.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3370-7 [12810673.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):419-24 [14624223.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5721-32 [15199129.001]
  • [Cites] J Mol Med (Berl). 2004 Aug;82(8):488-99 [15168026.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1021-30 [15299085.001]
  • [Cites] Ann Surg. 2005 May;241(5):748-56; discussion 756-8 [15849510.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):693-703 [15897233.001]
  • [Cites] J Biol Chem. 2006 Jan 20;281(3):1620-9 [16291753.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10473-81 [16469745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7625-30 [16684877.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10750-9 [17108111.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):559-67 [17014422.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11983-90 [17178897.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):284-9 [16847457.001]
  • [Cites] Mol Carcinog. 2007 Jun;46(6):476-87 [17295236.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1232-49 [18644986.001]
  • (PMID = 21129190.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATF3 protein, human; 0 / Activating Transcription Factor 3; 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  • [Other-IDs] NLM/ PMC3003660
  •  go-up   go-down


46. Chen J, Huang XF: The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther; 2009 Jul;8(14):1313-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The signal pathways in azoxymethane-induced colon cancer and preventive implications.
  • Colon cancer is the third most common cancer and third most common cause of cancer-related death in the USA according to 2008 American Cancer Society statistics.
  • The carcinogenesis of colon cancer has been associated with both genetics and environmental factors.
  • The 5 y survival rate of metastatic colon cancer is below 10%.
  • Azoxymethane (AOM) is a common model for colon cancer.
  • It can specifically induce colon cancer similar to the pathogenesis of human sporadic colon cancer.
  • Thus, it has been extensively used in the study of the molecular biology, prevention and treatment of colon cancer.
  • Mutation of K-ras activates this pathway and its downstream PI3K/Akt pathway and MAPK pathway.
  • This model has been used in the study of the genetic deficiencies of colon cancer and in the prevention and treatment of the disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLAZOXYMETHANOL .
  • Hazardous Substances Data Bank. METHYLAZOXYMETHANOL ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502780.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta2; 590-96-5 / methylazoxymethanol; 592-62-1 / Methylazoxymethanol Acetate; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; MO0N1J0SEN / Azoxymethane
  • [Number-of-references] 58
  •  go-up   go-down


47. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE: Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res; 2009 May 1;69(9):3842-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
  • Chemotherapeutic regimens for the treatment of colorectal cancer generally include oxaliplatin, although inherent and acquired resistance is common.
  • One potential mediator of oxaliplatin sensitivity is the nonreceptor protein tyrosine kinase, Src, the activity of which correlates with disease stage and patient survival.
  • These results suggest that Src inhibitors combined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indication of a molecular phenotype that might be susceptible to such combinations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1997 Nov;3(11):1233-41 [9359698.001]
  • [Cites] Free Radic Biol Med. 2008 Dec 1;45(11):1566-72 [18845245.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 21;1405(1-3):171-9 [9784629.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1397-404 [9816313.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Cell. 2000 Feb 4;100(3):293-6 [10676810.001]
  • [Cites] Int J Vitam Nutr Res. 2001 Jan;71(1):87-92 [11276929.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):344-51 [11900220.001]
  • [Cites] Mol Cell. 2002 Apr;9(4):725-37 [11983165.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1377-89 [12379772.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7797-807 [12420216.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8723-31 [12483525.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 19;309(2):377-83 [12951060.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2307-18 [15073106.001]
  • [Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7449-57 [15334062.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46113-21 [15326164.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070-4 [1348364.001]
  • [Cites] Chem Res Toxicol. 1992 Mar-Apr;5(2):227-31 [1322737.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):53-60 [7678609.001]
  • [Cites] J Surg Res. 1993 Apr;54(4):293-8 [7687314.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Sep 15;203(2):1175-80 [8093036.001]
  • [Cites] J Clin Invest. 1996 May 15;97(10):2268-76 [8636406.001]
  • [Cites] Nat Med. 1996 Jun;2(6):689-92 [8640562.001]
  • [Cites] Oncogene. 1996 Dec 19;13(12):2615-22 [9000135.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Feb;280(2):638-49 [9023274.001]
  • [Cites] Arch Surg. 1997 May;132(5):541-6 [9161399.001]
  • [Cites] Br J Cancer. 1997;76(2):206-10 [9231920.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):948-56 [15705895.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3110-20 [15735682.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6391-403 [16024778.001]
  • [Cites] Free Radic Biol Med. 2005 Sep 1;39(5):696-703 [16085187.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7214-22 [16103072.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10381-8 [16288028.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):236-44 [16478742.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1398-401 [16533761.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53 [16857785.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):573-84 [17625587.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8240-7 [17804738.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7232-6 [18094400.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):109-20 [18182619.001]
  • [Cites] Oncogene. 2008 Aug 21;27(36):4877-87 [18454177.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1052-7 [9422768.001]
  • (PMID = 19383922.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA09599; United States / NCI NIH HHS / CA / L30 CA124227-02; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / K23 CA136980; United States / NCI NIH HHS / CA / L30 CA124227; United States / NCI NIH HHS / CA / CA136980-01; United States / NCI NIH HHS / CA / CA124227-02; United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / K23 CA136980-01; United States / NCI NIH HHS / CA / U54 CA090810; United States / NCI NIH HHS / CA / T32 CA009599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Reactive Oxygen Species; 0 / Thiazoles; 0 / Vascular Endothelial Growth Factor A; 04ZR38536J / oxaliplatin; EC 2.7.10.2 / src-Family Kinases; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ NIHMS98199; NLM/ PMC2709758
  •  go-up   go-down


48. Sahakitrungruang C, Kanjanasilp P, Pattana-Arun J, Tantiphlachiva K, Rojanasakul A: Outcome of familial adenomatous polyposis: a retrospective study. J Med Assoc Thai; 2006 Sep;89 Suppl 3:S155-60
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Familial adenomatous polyposis (FAP) is characterized by the presence of numerous colorectal adenomatous polyps that progress to colorectal cancer if left untreated.
  • Following colorectal cancer, periampullary cancer and aggressive desmoid tumor are also the common causes of death.
  • Seventeen of the 29 patients (58.6%) had a family history of FAP Sixteen of 29 patients were discovered with colorectal cancer with a mean age of34.56 years.
  • Mucous bloody stool was the most common presenting symptom and most of the patients with this symptom (11/13) already had colorectal cancer Gastroduodenal polyps and desmoid tumor were common extracolonic manifestations.
  • The mean age ofpatients with colon cancer was older than the mean age ofpatients without colon cancer However, there was no significant difference between the two groups.
  • On the follow up period, two patients in the later group died of desmoid tumor and pancreatic cancer while seven patients in the former group died of metastatic colon cancer and one with desmoid tumor CONCLUSION: The proportion ofpatients who were discovered with colorectal cancer in the present study was high with young age onset of cancer Moreover, patients in this group had poorer outcome compared to the group of patients without colorectal cancer; of which, metastatic colorectal cancer was the major cause of death.
  • This result may be due to aggressiveness and advanced stage of disease at the first diagnosis.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718282.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


49. Compoginis JM, Richeimer SH, Brody GS: Placement of an implantable drug delivery system under the breast. Pain Med; 2007 Sep;8(6):521-4
Hazardous Substances Data Bank. HYDROMORPHONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT: The patient was a 52-year-old female with metastatic colon cancer and chronic flank pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716326.001).
  • [ISSN] 1526-2375
  • [Journal-full-title] Pain medicine (Malden, Mass.)
  • [ISO-abbreviation] Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Analgesics, Opioid; 0 / Anesthetics, Local; 7IO5LYA57N / ropivacaine; Q812464R06 / Hydromorphone
  •  go-up   go-down


50. Berber E, Siperstein AE: Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc; 2007 Apr;21(4):613-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiofrequency thermal ablation (RFA) is gaining increased acceptance for the treatment of unresectable primary and metastatic liver tumors.
  • The pathology was metastatic colon cancer for 244 patients (47%), hepatocellular cancer for 109 patients (21%), metastatic neuroendocrine cancer for 74 patients (14%), and other noncolorectal, nonneuroendocrine liver metastasis for 94 patients (18%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Immunohistochemistry. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Probability. Prospective Studies. Regression Analysis. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2000 Apr;14(4):400-5 [10790563.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Surg Endosc. 2005 May;19(5):710-4 [15759186.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1613-7 [16247574.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] J Urol. 1961 Sep;86:321-9 [13763692.001]
  • [Cites] J Vasc Interv Radiol. 1992 May;3(2):291-7 [1627876.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • (PMID = 17287917.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Seleye-Fubara D, Gbobo I: Pathological study of colorectal carcinoma in adult Nigerians: a study of 45 cases. Niger J Med; 2005 Apr-Jun;14(2):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest site of this cancer is the rectum and the least occurred in the transverse colon.
  • Most of our patients presented with advanced cancer of stage IV & III of TNM classification (D and C of Astler-Coller System).
  • Patients present when the tumour is in an advanced stage hence poorer prognosis and the ages of the patents is about 10 years earlier than that of Caucasians.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Developing Countries. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nigeria / epidemiology. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083240.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


52. Handa K, Ohmura M, Nishime C, Hishiki T, Nagahata Y, Kawai K, Suemizu H, Nakamura M, Wakui M, Kitagawa Y, Suematsu M, Tsukada K: Phosphorescence-assisted microvascular O(2) measurements reveal alterations of oxygen demand in human metastatic colon cancer in the liver of superimmunodeficient NOG mice. Adv Exp Med Biol; 2010;662:423-9
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorescence-assisted microvascular O(2) measurements reveal alterations of oxygen demand in human metastatic colon cancer in the liver of superimmunodeficient NOG mice.
  • We aimed to examine metabolism of human cancer in vivo and utilized superimmunodeficient NOG mice as an experimental model of hepatic metastasis, where human colon cancer cell line HCT116 transfected with Venus, the mutant GFP was injected intrasplenically.
  • In this model, a majority of metastatic foci occurred in periportal regions but not in central regions.
  • Under these conditions, there was a negative correlation between the size of metastatic foci and the lobular O(2) consumption, suggesting that the tumor O(2) consumption is smaller than that in the residual liver.
  • At 2 weeks, portal PO(2) was significantly smaller than controls, while the central PO(2) was not comparably decreased, indicating that metastatic foci increased the O(2) consumption, while the residual liver decreased it.
  • These results suggest metastatic tumors derived from human colon cancer exhibit notable aerobic metabolism during their developmental process, compromising respiration of the rest of the tissue regenerated during tumor development.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204825.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


53. Neri B, Cipriani G, Grifoni R, Molinara E, Pantaleo P, Rangan S, Vannini A, Tonelli P, Valeri A, Pantalone D, Taddei A, Bechi P: Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer. Oncol Res; 2009;17(11-12):559-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
  • Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response.
  • Several phase II studies have tested other single agents and different gemcitabine-based regimens in pancreatic cancer, but both response and survival rates have remained low.
  • Irinotecan, a topoisomerase I inhibitor currently approved for the treatment of metastatic colon cancer, has also demonstrated improved response rate in patients with pancreatic cancer.
  • Our purpose was to determine the activity and toxicity of this regimen in patients with unresectable or metastatic pancreatic cancer.
  • Patients with histologically confirmed pancreatic adenocarcinoma received gemcitabine 1000 mg/m2 plus irinotecan 100 mg/m2 IV on days 1, 8, and 15 of a 28-day cycle for 6-8 months.
  • On the basis of this trial, the combination of gemcitabine plus irinotecan, administered in a weekly schedule and at this dose, is well tolerated and offers encouraging activity in the treatment of advanced and/or metastatic pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806786.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


54. Huerta S, Li HC: Bowel perforation from bevacizumab for the management of colorectal cancer. Anticancer Drugs; 2009 May;20 Spec No 2:S19-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel perforation from bevacizumab for the management of colorectal cancer.
  • Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor receptor pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer.
  • In this report, we discuss a patient with bowel perforation from bevacizumab for the treatment of metastatic colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352105.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, Bonavida B: In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide; 2009 May;20(3):182-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF.
  • Primary SW480 and metastatic SW620 colon cancer cells are resistant to CDDP-induced apoptosis.
  • Examination of tumor tissues from patients with colon cancer demonstrated a significant downregulation of AIF in patients with advanced disease.
  • Altogether, these findings underscore the potential therapeutic application of NO donors and subtoxic chemotherapeutic drugs in the treatment of advanced colon cancer resistant to conventional chemotherapeutic agents.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105980.001).
  • [ISSN] 1089-8611
  • [Journal-full-title] Nitric oxide : biology and chemistry
  • [ISO-abbreviation] Nitric Oxide
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor; 0 / Nitric Oxide Donors; 0 / Nitroso Compounds; 0 / RNA, Small Interfering; 146724-94-9 / 2,2'-(hydroxynitrosohydrazono)bis-ethanamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Ohsawa I, Murakami T, Uemoto S, Kobayashi E: In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats. Transplantation; 2006 Jun 15;81(11):1558-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats.
  • BACKGROUND: Immunosuppressed individuals undergoing organ transplantation are at increased risk of recurrences of initial cancers, although how immunosuppressive therapy increases early cancer metastasis remains unclear.
  • METHODS: The metastatic fate of luciferase-expressing rat metastatic colon cancer cells (luc-RCN-H4) injected intravenously into the liver of syngeneic and allogeneic rats was examined in the presence of the immunosuppressant cyclosporin A (CsA) by in vivo luminescent technique.
  • CONCLUSIONS: Whereas the chemokine receptor expression by cancer cells is implicated with early organotropic dissemination even under CsA-mediated immune suppression, rather, CsA enhances the late-phase progression after tumor adhesion through TGF-beta1 expression.
  • [MeSH-minor] Animals. Benzamides / pharmacology. Blotting, Western. Cell Adhesion. Cell Line, Tumor. Cell Movement / drug effects. Dioxoles / pharmacology. Disease Progression. Gene Expression Regulation, Neoplastic / drug effects. Killer Cells, Natural / drug effects. Killer Cells, Natural / pathology. Liver Neoplasms / genetics. Liver Neoplasms / immunology. Liver Neoplasms / secondary. Luminescence. Lymphatic Metastasis / immunology. Male. Neoplasm Metastasis / pathology. Rats. Rats, Inbred F344. Receptors, Chemokine / analysis. Receptors, Chemokine / genetics. Reperfusion Injury / pathology. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor beta / analysis. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta1

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770245.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide; 0 / Benzamides; 0 / Dioxoles; 0 / Receptors, Chemokine; 0 / Tgfb1 protein, rat; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


57. Kokura S, Yoshida N, Sakamoto N, Ishikawa T, Takagi T, Higashihara H, Nakabe N, Handa O, Naito Y, Yoshikawa T: The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB. Cancer Lett; 2005 Nov 18;229(2):223-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB.
  • The transcription factor NF-kappaB is reportedly activated by anti-cancer chemotherapeutic compounds in many cancer cell lines and NF-kappaB activation is one mechanism by which tumors become resistant to apoptosis.
  • These results demonstrate that the combination of edaravone with CPT-11 may constitute a new strategy for treating primary and metastatic colon cancer.

  • Hazardous Substances Data Bank. 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095811.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Free Radical Scavengers; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 7673326042 / irinotecan; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; S798V6YJRP / phenylmethylpyrazolone; T3CHA1B51H / Antipyrine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


58. Polite BN, Dignam JJ, Olopade OI: Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am; 2005 Jul;89(4):771-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites.
  • Certainly, issues surrounding screening for CRC remain important in understanding the advanced stage of presentation for African Americans.
  • Importantly, even if one were able to eliminate the differences in stage at presentation between African Americans and whites, a survival disadvantage, albeit a much smaller one, would likely persist.
  • This becomes even more important as the life-prolonging options for treating both localized and metastatic colon cancer continue to multiply.
  • Finally, the apparent greater disparity in outcome for African Americans who have stage II disease should be explored in more detail, because this could have an immediate impact on treatment recommendations.
  • For example, a 23-gene signature was recently found to be predictive of recurrence among patients with Dukes B colon cancer [66].


59. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK, Lee WY, Park YS: The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol; 2010 Dec;27(4):1277-85
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
  • Colon cancer with DNA mismatch repair (MMR) defects reveals distinct clinical and pathologic features, including a better prognosis but reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • A current standard treatment for recurrent or metastatic colon cancer uses capecitabine plus oxaliplatin (CAPOX), or continuous-infusion fluorouracil plus oxaliplatin (FOLFOX).
  • This study investigated the effect of MMR status on the treatment outcomes for CAPOX and FOLFOX as first-line combination chemotherapy in recurrent or metastatic colon cancer.
  • We analyzed 171 patients who had been treated with CAPOX or FOLFOX as first-line combination chemotherapy in recurrent or metastatic colon adenocarcinoma between February 2004 and July 2008.
  • The incidence of colon cancer with MMR defect was 10/171 (6%).
  • Colon cancers with MMR defect (MSI-H and/or MMR-D) are more commonly located in proximal to the splenic flexure (p=0.03).
  • The MMR status did not significantly influence the overall response (p=0.95) to first-line CAPOX or FOLFOX treatment in patients with recurrent or metastatic colon cancer.
  • According to the MMR status, there was no significant difference for PFS (p=0.50) and OS (p=0.47) in patients with recurrent or metastatic colon cancer treated with first-line CAPOX or FOLFOX.
  • In colon cancers with MMR defect, there was no significant difference for PFS (p=0.48) and OS (p=0.56) between CAPOX and FOLFOX as first-line combination chemotherapy.
  • The MMR status does not predict the effect of oxaliplatin-based combination chemotherapy as 1st line in recurrent or metastatic colon cancers.
  • CAPOX in the first-line treatment of recurrent or metastatic colon cancer with MMR intacts showed a superior OS compared with FOLFOX unlike colon cancer with MMR defects.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / genetics. DNA Mismatch Repair / drug effects. Microsatellite Instability / drug effects. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Immunoenzyme Techniques. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Polymerase Chain Reaction. Prognosis. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949897.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Karlsson M, Nilsson O, Thörn M, Winqvist O: Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry. J Immunol Methods; 2008 May 20;334(1-2):122-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry.
  • In colon cancer the presence of metastases in the regional lymph nodes is an important prognostic factor.
  • In this study the possible use of flow cytometry for detection of sentinel node metastases in patients with colon cancer has been investigated.
  • Peripheral blood mononuclear cells (PBMC) with the addition of DLD-1 colon cancer cells were stained intracellularly for cytokeratin 20 (CK20), and for the cell surface markers epithelial cell adhesion molecule (EpCAM) and carbohydrate antigen 19-9 (CA19-9).
  • CK20 positive colon cancer cells were reliably detected with as few as 0.037% events.
  • However, PBMCs from both colon cancer patients and from healthy individuals contained CK20 positive cells.
  • The use of flow cytometry for detection of metastatic colon cancer cells was verified in fourteen sentinel nodes specimens from patients with colon cancer.
  • Herein we have explored the potential of flow cytometry to become a fast, sensitive and reliable method for detection of lymphatic metastases in patients with colon cancer using direct fluorophore-conjugated antibodies against multiple surface antigens.
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / immunology. CA-19-9 Antigen / analysis. CA-19-9 Antigen / immunology. Cell Adhesion Molecules / analysis. Cell Adhesion Molecules / immunology. Cell Line, Tumor. Humans. Keratin-20 / analysis. Keratin-20 / immunology. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377923.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CA-19-9 Antigen; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Keratin-20
  •  go-up   go-down


61. Díez-Fernández R, Salinas Hernández P, Girón-Duch C: [A review of chemotherapy for metastatic colon cancer]. Farm Hosp; 2006 Nov-Dec;30(6):359-69
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A review of chemotherapy for metastatic colon cancer].
  • [Transliterated title] Revisión del tratamiento quimioterápico del cáncer de colon metastásico.
  • OBJECTIVE: To report and discuss the results of clinical trials published concerning chemotherapy for metastatic colorectal cancer in order to elucidate and define treatment guidelines.
  • CONCLUSIONS: New drugs for metastatic colorectal cancer open up new therapy lines allowing increasingly improved survival.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298193.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; FCB9EGG971 / raltitrexed; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 41
  •  go-up   go-down


62. Iwashita Y, Sasaki A, Matsumoto T, Shibata K, Inomata M, Ohta M, Kitano S: Two-stage laparoscopic resection of colon cancer and metastatic liver tumour. J Minim Access Surg; 2005 Mar;1(1):37-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage laparoscopic resection of colon cancer and metastatic liver tumour.
  • We report herein the case of 70-year-old woman in whom colon cancer and a synchronous metastatic liver tumour were successfully resected laparoscopically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2000 Apr;135(4):473-9; discussion 479-80 [10768715.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] Surg Today. 2003;33(11):833-8 [14605955.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):213-6 [15036198.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • (PMID = 21234143.001).
  • [ISSN] 0972-9941
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3016475
  • [Keywords] NOTNLM ; Colorectal cancer / laparoscopic hepatectomy / laparoscopy-assisted colectomy / metastatic liver tumour
  •  go-up   go-down


63. Gallagher DJ, Libby DM, Kemeny N: Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancer. Clin Colorectal Cancer; 2009 Jul;8(3):172-4
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancer.
  • When patients with colorectal cancer are monitored after resection of primary or metastatic disease, an elevated carcinoembryonic antigen (CEA) level is usually an indicator of recurrent disease.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoembryonic Antigen / blood. Colonic Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Sarcoidosis, Pulmonary / radionuclide imaging

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632934.001).
  • [ISSN] 1938-0674
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR: Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther; 2007 Feb;14(2):139-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver.
  • To further understand the basis for the minimal hepatic toxicity of adenoviral vectors, we evaluated the replication of adenovirus in primary hepatocytes and tumor cells in culture and the expression of the coxsackie-adenoviral receptor (CAR) in normal liver and colon cancer metastatic to the liver.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139321.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ONYX015; 0 / Receptors, Virus; 0 / Viral Vaccines; 0 / adenovirus receptor
  •  go-up   go-down


65. Melmed GY, Devlin SM, Vlotides G, Dhall D, Ross S, Yu R, Melmed S: Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis. Clin Gastroenterol Hepatol; 2008 Mar;6(3):360-3
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis.
  • METHODS: We report the case of a 68-year-old man with colonic Crohn's disease who was found to have aggressive metastatic colon cancer.
  • Normal and malignant colonic tissue was examined for qualitative and quantitative molecular profiles of growth hormone (GH) and its signaling molecules, using immunohistochemistry and RNA extraction with polymerase chain reaction amplification.
  • RESULTS: Immunoreactivity was more robust in tumor tissue than in normal colon for insulin-like growth factor-1 receptor (IGF-1R) but not for IGF, GH, or GH receptor.
  • CONCLUSIONS: Colorectal cancer development concurrent with administration of HGH for anti-aging purposes occurred in an individual already at increased risk for colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 27;360(9329):273-7 [12147369.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1030-5 [11861378.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] N Engl J Med. 2000 Jun 1;342(22):1633-7 [10833209.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29483-8 [8910616.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] Inflamm Bowel Dis. 2004 Nov;10(6):871-80 [15626905.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2086-90 [16249424.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1632-41 [16410303.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):119 [16932266.001]
  • [Cites] Gastroenterol Clin North Am. 2006 Sep;35(3):553-71 [16952740.001]
  • [Cites] Ann Intern Med. 2007 Jan 16;146(2):104-15 [17227934.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5351-2 [12466319.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):779-80 [12606731.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):350-7 [12878742.001]
  • [Cites] Endocr Pract. 2003 Jan-Feb;9(1):64-76 [12917095.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):570-81 [15300589.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):452-9 [8050827.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2086-95 [12412161.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):659 [7993846.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1128-33 [10534157.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):345-9 [10794477.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1377-89 [12379772.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V13-4 [12221033.001]
  • (PMID = 18255351.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-10; United States / NCI NIH HHS / CA / R01 CA075979; United States / NIDDK NIH HHS / DK / T32 DK007180; United States / NCI NIH HHS / CA / R01 CA075979-10
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone
  • [Other-IDs] NLM/ NIHMS54361; NLM/ PMC2696478
  •  go-up   go-down


66. Lai E, Singh R, Teng B, Zhao Y, Sharratt E, Howell G, Rajput A, Bullard Dunn K: Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth in mice. Dis Colon Rectum; 2010 Apr;53(4):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth in mice.
  • PURPOSE: Hyaluronan and hyaluronan synthases have been implicated in cancer progression.
  • Hyaluronan synthase-3 is up-regulated in metastatic colon cancer cells (SW620), and its expression mediates cellular growth in vitro.
  • We hypothesized that inhibition of hyaluronan synthase-3 would decrease tumor formation and/or alter the pattern of metastasis in mouse models of colon cancer growth.
  • CONCLUSION: Inhibition of hyaluronan synthase-3 expression in SW620 colon cancer cells decreases subcutaneous tumor growth in mice, but has less of an effect on lung and liver metastases.
  • This observation suggests that hyaluronan synthase-3 may enhance primary colon cancer growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305449.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.212 / hyaluronan synthase
  •  go-up   go-down


67. Xu F, Ye YJ, Liu W, Kong M, He Y, Wang S: Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice. Scand J Gastroenterol; 2010 Jun;45(6):707-13
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice.
  • OBJECTIVE: Colorectal cancer (CRC) is one of the most common malignancies in the western world.
  • Although surgical resection is the first choice worldwide, at this point an effective approach for the treatment of patients with liver metastasis and cancer recurrence postoperation has not yet been found.
  • The aim of this study is to investigate the role of the allogeneic dendritomas from fusion of DCs and metastatic colon cancer cells in the activation of anti-tumor immunity against colorectal cancer liver metastases.
  • MATERIAL AND METHODS: Hybrids were generated by fused allogeneic human peripheral blood dendritic cells with metastatic colon cancer SW620 cells using 50% polyethylene glycol (PEG).
  • CONCLUSIONS: Vaccination with hybrids can induces strong cellular responses and significant protection from challenge in SCID mouse metastatic CRC model.


68. Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM: Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther; 2009 Nov;8(11):3001-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
  • We assessed the antitumor efficacy of OBP-301 and the ability of OBP-401 to deliver GFP in hepatocellular carcinoma (HCC) and metastatic colon cancer nude mouse models.
  • We showed that i.v. administration of OBP-301 significantly inhibited colon cancer liver metastases and orthotopically implanted HCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2006 Feb 1;312(3):256-65 [16356494.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3848-56 [16799626.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6259-65 [15342413.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92 [14734481.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii13-6 [12810452.001]
  • [Cites] Cancer Gene Ther. 2008 May;15(5):315-22 [18274558.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):303-6 [10326848.001]
  • [Cites] Hepatogastroenterology. 2007 Dec;54(80):2232-9 [18265640.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):385-90 [18201270.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):337-52 [9019355.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3130-40 [15735729.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1213-9 [17013385.001]
  • [Cites] Biotechniques. 2005 Aug;39(2):170, 172 [16116787.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):225-37 [10728807.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):551-7 [9973199.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):432-40 [16477640.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2628-33 [18338751.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):29-34 [12832962.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1528-38 [18754863.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8490-9 [16230676.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1848-52 [2477137.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • (PMID = 19887549.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R43 CA132242; United States / NCI NIH HHS / CA / CA132242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


69. Grivas AA, Trafalis DT, Athanassiou AE: Implication of bevacizumab in fatal arterial thromboembolic incidents. J BUON; 2009 Jan-Mar;14(1):115-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bevacizumab, a humanized monoclonal antibody against vascular endothelial factor (VEGF), is approved for the treatment of metastatic colon cancer, but it has also shown efficacy in first line therapy of non-squamous-cell non-smallcell lung cancer, breast cancer and clear-cell renal cancer.
  • We describe and discuss two cases of cancer patients who developed fatal arterial thromboembolic episodes after administration of bevacizumab.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365880.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Anticoagulants; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


70. Agarwal V, Sgouros J, Smithson J, Lodge JP, Razack A, Campbell A, Maraveyas A: Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. J Med Case Rep; 2008;2:227

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report.
  • INTRODUCTION: We present the case of a patient with colon cancer who, while receiving bevacizumab, developed sinusoidal obstruction syndrome (veno-occlusive disease) (SOSVOD).
  • CASE PRESENTATION: A 77-year-old man was being treated with oxaliplatin and a modified de Gramont regimen of 5-fluorouracil for metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Mar;15(3):460-6 [14998849.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] J Cell Mol Med. 2005 Oct-Dec;9(4):777-94 [16364190.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9073-8 [16361615.001]
  • (PMID = 18620573.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2481264
  •  go-up   go-down


71. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W: Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res; 2008 May 1;68(9):3467-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that in two tumor models (the CT-26 metastatic colon cancer and the 15-12RM fibrosarcoma regressor models), this counter-surveillance mechanism requires the expression of a novel IL-13 receptor, IL-13R alpha(2), on Gr-1(intermediate) cells, because down-regulation of IL-13R alpha(2) expression or the activator protein-1 signal generated by the receptor via in vivo administration of specific small interfering RNA or decoy oligonucleotides leads to loss of TGF-beta(1) production.
  • Taking advantage of this latter fact, we then show in the CT-26 model that counter-immunosurveillance can be inhibited, anti-CT-26-specific CD8(+) cytolytic activity can be restored, and CT-26 metastatic tumor nodules can be greatly decreased by administration of TNF-alpha R-Fc.
  • These studies point to the prevention of metastatic cancer with an available agent with already known clinically acceptable adverse effects and toxicity.
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Down-Regulation. Drug Delivery Systems. Drug Evaluation, Preclinical. Female. Interleukin-13 / metabolism. Interleukin-13 / pharmacology. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Signal Transduction / drug effects. Survival Analysis. Transforming Growth Factor beta1 / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):464-71 [12504107.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):287-98 [11880205.001]
  • [Cites] J Exp Med. 2003 Mar 17;197(6):687-701 [12642601.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):677-90; quiz 691 [12704343.001]
  • [Cites] Science. 2003 Jun 6;300(5625):1527-8 [12791978.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1741-52 [14657224.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):79-85 [14610620.001]
  • [Cites] Hepatology. 2004 Mar;39(3):676-87 [14999686.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):583-94 [15286725.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):6602-7 [8245488.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2317-24 [9725226.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):184-93 [10384115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 [15623559.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64(11):1557-62 [15843448.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):369-80 [16286245.001]
  • [Cites] Nat Med. 2006 Jan;12(1):99-106 [16327802.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):7905-12 [17114462.001]
  • [Cites] Neoplasma. 2006;53(6):478-84 [17167715.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1038-45 [17283136.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5859-70 [17442970.001]
  • [Cites] J Rheumatol. 2007 Dec;34(12):2334-42 [17985409.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1063-70 [10856136.001]
  • [Cites] Surgery. 2001 Feb;129(2):176-87 [11174711.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):515-20 [11101874.001]
  • [Cites] Annu Rev Immunol. 2003;21:425-56 [12615888.001]
  • (PMID = 18451175.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI000432-23
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / RNA, Small Interfering; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ NIHMS119905; NLM/ PMC2746996
  •  go-up   go-down


72. Zacharia TT, Saini S, Halpern EF, Sumner JE: CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR Am J Roentgenol; 2006 Apr;186(4):1067-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.
  • OBJECTIVE: We sought to define the ideal number of target lesions to be measured to assess disease response in patients undergoing chemotherapy for colon cancer metastases to the liver.
  • Patients were part of a multisite, randomized, double-arm, phase 3 clinical trial involving chemotherapy with an investigational drug for metastatic colon cancer.
  • CONCLUSION: In the majority of patients with hepatic metastases of colorectal cancer, measuring the maximal diameter of the single largest lesion yielded the same treatment-response classification as measuring up to five target lesions.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2006 Nov;187(5):W552; author reply W553 [17056892.001]
  • (PMID = 16554580.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH: Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol; 2006 Mar;81(3):193-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thrombocytopenia developing in the course of chemotherapy for malignant disease is usually attributed to drug-induced marrow suppression and/or marrow replacement by tumor.
  • We describe two patients who developed severe thrombocytopenia and hemorrhagic symptoms while being treated with oxaliplatin, 5-fluorouracil, and leukovorin for metastatic colon cancer in whom platelet destruction appears to have been caused by oxaliplatin-dependent antibodies specific for the platelet glycoprotein IIb/IIIa complex (alpha(IIb)/beta(3) integrin).

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493620.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL013629; United States / NHLBI NIH HHS / HL / HL-13629
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Autoantibodies; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Nakamura M, Kobashikawa K, Tamura J, Takaki R, Ohshiro M, Matayoshi R, Hirata T, Kinjyo F, Fujita J: [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer]. Nihon Shokakibyo Gakkai Zasshi; 2009 Dec;106(12):1744-50
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer].
  • A 79-year-old woman with colon cancer and multiple liver metastases was admitted to our hospital for systemic chemotherapy.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966516.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 25
  •  go-up   go-down


75. Bir AS, Fora AA, Levea C, Fakih MG: Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer Res; 2009 Feb;29(2):465-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes.
  • Spontaneous remissions have been reported in solid tumors such as melanoma and renal cell cancer.
  • However, spontaneous remissions in colon cancer have not been previously radiographically confirmed.
  • A case of colon cancer metastatic to the retroperitoneal lymph nodes that exhibited a durable spontaneous regression is reported.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Neoplasm Regression, Spontaneous


76. Karoui M, Charachon A, Delbaldo C, Loriau J, Laurent A, Sobhani I, Tran Van Nhieu J, Delchier JC, Fagniez PL, Piedbois P, Cherqui D: Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration. Arch Surg; 2007 Jul;142(7):619-23; discussion 623
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration.
  • PATIENTS: From January 1, 1996, to September 15, 2005, 58 patients with obstructing colon cancer and nonresectable synchronous metastases were treated with self-expanding colonic metallic stent (SEMS) (n = 31) or surgery (n = 27).
  • MAIN OUTCOME MEASURES: Comparison of the use of SEMS and emergency surgery as palliative measures to treat obstructing colon cancer with special reference to time to chemotherapy administration and survival.
  • CONCLUSIONS: Insertion of SEMS should be the first step to treat obstructing colon cancer with nonresectable synchronous metastases because it allows chemotherapy to be administered earlier, may increase the resectability rate of metastases, and favorably impacts survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Colectomy. Female. Hepatectomy. Hospitalization. Humans. Length of Stay. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Surgical Stomas. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638798.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


77. Xu F, Ye YJ, Cui ZR, Wang S: Allogeneic dendritomas induce anti-tumour immunity against metastatic colon cancer. Scand J Immunol; 2005 Apr;61(4):364-9
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic dendritomas induce anti-tumour immunity against metastatic colon cancer.
  • Colon cancer (CC) is one of the most common malignancies in the Western world.
  • Although surgical resection is the first choice worldwide, at this point an effective approach for the treatment of patients with metastasis and cancer recurrence post-operation has not yet been found.
  • The aim of this study was to investigate the role of the allogeneic dendritomas from fusion of dendritic cells (DC) and metastatic CC cells in the activation of anti-tumour immunity against metastatic CC.
  • Dendritomas were generated by fused allogeneic human peripheral blood DC with metastatic CC cells using 50% polyethylene glycol.
  • These results demonstrate that allogeneic dendritomas activate T-cell responses against metastatic CC cells.
  • [MeSH-minor] Cell Fusion. Flow Cytometry. Humans. Immunophenotyping. Lymphocyte Activation. Neoplasm Metastasis. Polyethylene Glycols. T-Lymphocytes, Cytotoxic / cytology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853920.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


78. Raftery L, Goldberg RM: Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J; 2010 May-Jun;16(3):214-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal delivery of cytotoxic chemotherapy for colon cancer.
  • Colon cancer is treated adjuvantly with 5-flourouracil (5-FU) and oxaliplatin, most commonly as part of the FOLFOX regimen, which has less toxicity than the older regimen FLOX (bolus 5-FU and oxaliplatin) that has fallen out of favor.
  • Patients with metastatic disease may be treated with a number of regimens, including FOLFOX and FOLFIRI; however, the environment is a not a monotonous vanilla and chocolate FOLFOX and FOLFIRI.
  • Cytotoxic agents, sequentially or in combination, are frequently combined with biologic agents to improve response in metastatic disease.
  • Clinical investigators have focused considerable attention on how best to apply all the agents active in metastatic colon cancer, a practice in evolution.
  • In this article, we highlight important, informative research regarding cytotoxic chemotherapy for colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526099.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


79. Shin KS, Hong SB, Son BR: [A Case of Catheter-Related Bacteremia by Arthrobacter woluwensis.]. Korean J Lab Med; 2006 Apr;26(2):103-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arthrobacter woluwensis, a catalase-positive coryneform bacterium recognized as an opportunistic pathogen, was repeatedly isolated from the blood of a 56-year-old male patient with metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156709.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


80. Grammaticos P, Zerva C, Asteriadis I, Trontzos C, Hatziioannou K: Is hybridic positron emission tomography/computerized tomography the only option? The future of nuclear medicine and molecular imaging. Hell J Nucl Med; 2007 May-Aug;10(2):74-6
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • c) Although there is at present a list of indications suggested for the PET/CT scanner, there are studies disputing some of these indications, as for example in metastatic colon cancer where a high diagnostic accuracy for PET study alone, has been reported.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hell J Nucl Med. 2007 Sep-Dec;10(3):182 [18271144.001]
  • [CommentIn] Hell J Nucl Med. 2007 Sep-Dec;10(3):181 [18271143.001]
  • [CommentIn] Hell J Nucl Med. 2007 Sep-Dec;10(3):183 [18084662.001]
  • [CommentIn] Hell J Nucl Med. 2007 Sep-Dec;10(3):181 [18273956.001]
  • [CommentIn] Hell J Nucl Med. 2007 Sep-Dec;10(3):182 [18273957.001]
  • (PMID = 17684579.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Greece
  •  go-up   go-down


81. Garibaldi DC, Adler RA: Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg; 2007 Jan-Feb;23(1):62-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
  • Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways.
  • It has been shown to prolong survival in patients with metastatic colorectal cancer.
  • We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Scars.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237696.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


82. Huerta S, Goulet EJ, Livingston EH: Colon cancer and apoptosis. Am J Surg; 2006 Apr;191(4):517-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer and apoptosis.
  • BACKGROUND: The implementation of new therapeutic options for the management of metastatic colon cancer mandates a revisit to apoptosis and its role in colon cancer tumorigenesis with an emphasis on the mechanisms leading to chemotherapeutic resistance and immune system evasion of colon cancer cells.
  • DATA SOURCES: Literature regarding molecular apoptosis mechanisms and the role of apoptosis in colon cancer progression are reviewed by this article.
  • CONCLUSION: Programmed cell death has rapidly emerged as a potential target for cancer treatment at various stages of tumor progression.
  • Understanding how defects in the death receptor pathway of apoptosis permit colon cancer cells to escape the immune system would allow for treatment options whereby the body's immune system could again recognize and eliminate unwanted cells.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cell Transformation, Neoplastic. Disease Progression. Humans. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531147.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 103
  •  go-up   go-down


83. Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, Rota-Scalabrini D, Geuna M, Fizzotti M, Sangiolo D, Sottile A, De Rosa G, Bucci AR, Lambertenghi-Deliliers G, Benedetti E, Nash R, Aglietta M: Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood; 2006 May 1;107(9):3795-803
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.
  • Fifteen patients with metastatic CRC underwent HCT from human leukocyte antigen (HLA)-matched siblings after a nonmyeloablative conditioning regimen.
  • Eight patients experienced grades II to IV acute graft-versus-host disease (GVHD).

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403911.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen
  •  go-up   go-down


84. Gupta N, Miyauchi S, Martindale RG, Herdman AV, Podolsky R, Miyake K, Mager S, Prasad PD, Ganapathy ME, Ganapathy V: Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta; 2005 Jun 30;1741(1-2):215-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans.
  • ATB(0,+) (SLC6A14) is a Na(+)/Cl(-)-coupled arginine transporter expressed at low levels in normal colon.
  • Since arginine and arginine-derived nitric oxide (NO) play a critical role in cancer, we examined the expression of ATB(0,+) in colorectal cancer.
  • Paired normal and cancer tissues from colectomy specimens of 10 patients with colorectal cancer and from the liver tissue of one patient with hepatic metastasis from a colonic primary were used for the analysis of the levels of ATB(0,+) mRNA, inducible NOS (iNOS) mRNA and the corresponding proteins.
  • Tissues samples from the colon, liver, and lymph nodes of an additional patient with metastatic colon cancer were analyzed for ATB(0,+) protein alone.
  • The ATB(0,+) mRNA increased 22.9+/-3.0-fold in colorectal cancer compared to normal tissue and the increase was evident in each of the 10 cases examined. iNOS mRNA increased 5.2+/-1.1-fold in cancer specimens.
  • This study strongly suggests that the upregulation of ATB(0,+) may have a pathogenic role in colorectal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis / genetics. Nitric Oxide Synthase / analysis. Nitric Oxide Synthase / metabolism. Nitric Oxide Synthase Type II. RNA, Messenger / analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905073.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 65344
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems, Basic; 0 / RNA, Messenger; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


85. Marshall JL: Managing potentially resectable metastatic colon cancer. Gastrointest Cancer Res; 2008 Jul;2(4 Suppl):S23-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing potentially resectable metastatic colon cancer.
  • For patients with metastatic colon cancer, management has evolved from resecting a single liver metastasis and having only one chemotherapy medicine, to resecting multiple metastases including those outside the liver as well as using combination chemotherapy (based on recent supportive trials) to improve outcomes.
  • This paper briefly discusses important issues regarding the new management paradigm for patients with resectable metastases from colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4853-5 [16051943.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Arch Surg. 2006 May;141(5):460-6; discussion 466-7 [16702517.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10):1261-8 [16947009.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):52-8 [12513961.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):933-9 [15151951.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):425-9 [15677624.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Annu Rev Med. 2005;56:139-56 [15660506.001]
  • (PMID = 19343144.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2661554
  •  go-up   go-down


86. McCormick CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow RE: The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol; 2007 Jun;105(3):791-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery for colon cancer metastatic to the ovary.
  • OBJECTIVE: We sought to further elucidate the survival impact of cytoreductive surgery among patients with colon cancer metastatic to the ovary.
  • METHODS: All women diagnosed with primary colon cancer metastatic to the ovary at a single institution from 1980 to 2005 were retrospectively identified.
  • RESULTS: A total of 39 patients with 40 cases of colon cancer metastatic to the ovary were identified.
  • Patients with metastatic disease confined to the ovaries (n=11) had a median overall survival (OS) time of 61 months (range 15-120) compared to 17 months (range 0.5-73) for those with more extensive metastases (n=24) (p=0.0428).
  • CONCLUSIONS: The observation that optimal cytoreduction was associated with prolonged PFS and OS in both patients with localized ovarian and widespread metastases of colon cancer suggests a role for surgical management of metastatic colon cancer in women.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408727.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Vaidyanathan G, Fakih MG: A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver. Anticancer Res; 2010 Feb;30(2):677-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver.
  • Colon cancer is the second leading cause of cancer death in the United States.
  • Patients with colon cancer metastatic to liver and bone are deemed non-curable and have a poor prognosis.
  • We present a case of recurrent colon cancer with synchronous hepatic and bony metastases treated with radiation, chemotherapy, and curative-intent hepatectomy.


88. Chin SN, Kim TK, Siu LL: Hepatic steatosis secondary to capecitabine: a case report. J Med Case Rep; 2010;4:227

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With increasing use of capecitabine since its approval for the treatment of metastatic colon cancer in 2001, and more recently for adjuvant treatment of colon cancer and treatment of metastatic breast cancer, we can anticipate increased recognition of potential toxicities associated with this 5-fluorouracil derivative.
  • CASE PRESENTATION: We report the case of a 74-year-old Armenian woman who received capecitabine as adjuvant treatment for colon cancer and subsequently developed abnormal liver biochemical tests and radiographic findings in keeping with hepatic steatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24576340.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2916012
  •  go-up   go-down


89. Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S, Altomare DF, Correale M: Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol; 2010 Mar;32(1):160-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients.
  • In our study, we have evaluated levels of both glycoproteins in sera of non metastatic colon cancer patients.
  • Interestingly, galectin-3 ranged higher in cancer patients than in controls (p<0.0001), particularly in more differentiated tumors (p<0.04).
  • Moreover, 90K mean values ranged higher in right-side than in left-side colon cancer.
  • In conclusion, serum galectin3 might represent a useful biomarker to evaluate colon cancer transformation and, together with its ligand 90K, could contribute to the characterization of colon cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, Neoplasm. Biomarkers, Tumor. Female. Galectin 3 / blood. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686089.001).
  • [ISSN] 1532-2513
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Galectin 3; 0 / Glycoproteins; 0 / LGALS3BP protein, human
  •  go-up   go-down


90. Shaikh A, Wiisanen ME, Gunderson HD, Leung N: Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. Ann Pharmacother; 2009 Jul;43(7):1370-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 77-year-old female with metastatic colon cancer presented with vomiting and diarrhea.
  • The patient had been diagnosed with stage IIIC (T3, N2, M0) colon cancer 18 months earlier and was initially treated with FOLFOX6 (regimen of oxaliplatin, fluorouracil, and leucovorin) after her hemicolectomy.
  • She did well until 10 months after her cancer diagnosis, when metastasis was discovered.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584382.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


91. Gongora C, Candeil L, Vezzio N, Copois V, Denis V, Breil C, Molina F, Fraslon C, Conseiller E, Pau B, Martineau P, Del Rio M: Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biol Ther; 2008 Jun;7(6):822-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
  • Irinotecan is a topoisomerase I inhibitor widely used as an anticancer agent in the treatment of metastatic colon cancer.
  • We have isolated a colon carcinoma cell line, HCT116-SN6, which displays a 6-fold higher resistance to SN38, the active metabolite of irinotecan.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Camptothecin / analogs & derivatives. Cell Proliferation. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Drug Resistance, Neoplasm. Interferons / metabolism


92. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Larrañga J: Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative. Med Oncol; 2006;23(1):91-104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative.
  • INTRODUCTION: Advanced colon cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal.
  • PATIENTS AND METHODS: Metastatic colon cancer patients chemotherapy-resistant, high CEA plasma levels, in progression, were 2-group randomized.
  • CONCLUSION: The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645234.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


93. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA: Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther; 2005 May;4(5):548-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.
  • The virtual lack of well-characterized metastatic pancreatic cancer tissues for study has limited systematic studies of the metastatic process of this deadly disease.
  • To address this important issue, we have instituted a rapid autopsy protocol for the collection of high quality tissues from patients with metastatic pancreatic cancer, called the Gastrointestinal Cancer Rapid Medical Donation Program (GICRMDP).
  • At the time of preparation of this manuscript, 20 patients with metastatic pancreatic cancer and one patient with metastatic colon cancer have undergone a rapid autopsy in association with the GICRMDP.
  • The average time interval achieved for these 21 patients was 8.0 hours, with more than 500 individual samples of matched high quality primary and metastatic pancreatic cancer tissues, peritoneal/pleural fluid and blood obtained so far.
  • In an initial survey of KRAS2, TP53 and DPC4 genetic status in lethal metastatic pancreatic cancers, activating KRAS2 mutations were detected in 82% of cases and inactivating TP53 mutations in 55% of cases, consistent with rates of genetic alteration of these genes in early stage pancreatic cancers.
  • However, DPC4 inactivation was found in 75% of patients analyzed, suggesting that genetic inactivation of the DPC4 tumor suppressor gene continues to be selected for with growth at the primary site and metastatic spread to other organs.
  • The invaluable tissue resources generated by the success of the GICRMDP will provide an unparalleled resource for study of metastatic pancreatic cancer and of the metastatic process in general.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8516-20 [15623633.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1038-45 [10741732.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96 [11072167.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3254-7 [11248065.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 2001 May;233(5):696-703 [11323508.001]
  • [Cites] Curr Opin Oncol. 2002 Jul;14(4):424-30 [12130928.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13 [12642681.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2585-8 [12750283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(2-3):155-64 [14716065.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):651-7 [15277238.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Nature. 1980 Jan 10;283(5743):139-46 [6985715.001]
  • [Cites] Nucleic Acids Res. 1988 Aug 25;16(16):7773-82 [3047672.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2761-4 [8168108.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3025-33 [8187092.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):125-34 [7848081.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4670-5 [7553647.001]
  • [Cites] Pancreas. 1995 Nov;11(4):345-9 [8532650.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2339-42 [9622070.001]
  • (PMID = 15846069.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106610-02; United States / NCI NIH HHS / CA / K08 CA106610; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / K08 CA106610-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS147166; NLM/ PMC2771924
  •  go-up   go-down


94. Zendah I, Ben Saad S, Daghfous H, Ayadi A, Toujani S, Merai S, Ben M'rad S, Tritar F: [Hydatid cyst of the chest wall mimicking metastatic colon cancer]. Rev Pneumol Clin; 2009 Dec;65(6):357-60
Hazardous Substances Data Bank. ALBENDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hydatid cyst of the chest wall mimicking metastatic colon cancer].
  • [Transliterated title] Kyste hydatique de la paroi thoracique mimant une métastase de cancer colique.
  • Therefore, metastastic colon cancer was suspected.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995657.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anthelmintics; F4216019LN / Albendazole
  •  go-up   go-down


95. Katsumata K, Sumi T, Wada T, Mori Y, Hisada M, Kawakita H, Enomoto M, Suzuki S, Matsuda D, Tsuchida A, Aoki T: Oxaliplatin for metastatic colon cancer in a patient with renal failure. Clin Med Oncol; 2008;2:97-101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin for metastatic colon cancer in a patient with renal failure.
  • OBJECTIVE: Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan.
  • In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin.
  • METHODS: A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m(2)) and l-leucovorin(l-LV) (200 mg/m(2)), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively.
  • RESULTS: The patient received 3 courses of oxaliplatin before he died of cancer.
  • Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):157-64 [10663631.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jul;30(7):318-21 [11007166.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Nov;27(13):2135-8 [11103248.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5970-6 [8261411.001]
  • [Cites] Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 [8951344.001]
  • [Cites] J Pharm Biomed Anal. 2000 Dec;24(1):1-10 [11108533.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Sep;14(9):2771-4 [3631976.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2664-72 [12860942.001]
  • (PMID = 21892270.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161642
  • [Keywords] NOTNLM ; colorectal cancer / hemodialysis / oxaliplatin / renal failure
  •  go-up   go-down


96. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I: Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging; 2007;24(8):643-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bevacizumab is a full-length anti-VEGF antibody that was originally approved for use in metastatic colon cancer and is under investigation as a low-cost off-label alternative for patients with AMD.

  • Genetic Alliance. consumer health - Macular Degeneration.
  • MedlinePlus Health Information. consumer health - Macular Degeneration.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702534.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Aptamers, Nucleotide; 0 / Vascular Endothelial Growth Factor A; 0 / pegaptanib; 2S9ZZM9Q9V / Bevacizumab; ZL1R02VT79 / Ranibizumab
  • [Number-of-references] 70
  •  go-up   go-down


97. Hoogerwerf WA: Biologic clocks and the gut. Curr Gastroenterol Rep; 2006 Oct;8(5):353-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the development of gastrointestinal complications after administration of aspirin and after chemo- and radiotherapy for metastatic colon cancer depends on the time of administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968601.001).
  • [ISSN] 1522-8037
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


98. Wolfsen HC, Hemminger LL: Salvage photodynamic therapy for persistent esophageal cancer after chemoradiation therapy. Photodiagnosis Photodyn Ther; 2006 Mar;3(1):11-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage photodynamic therapy for persistent esophageal cancer after chemoradiation therapy.
  • BACKGROUND: Locally advanced esophageal cancer may not be completely eradicated after chemoradiation therapy (CRT) and further treatment options are limited.
  • After upper endoscopy with biopsies documented neoplasm after CRT, patients were evaluated with contrast-enhanced computed tomography of the chest and abdomen as well as endoscopic ultrasound to confirm persistence/recurrence of only mucosal disease.
  • The other five patients treated for Barrett's carcinoma have remained disease free although one had died 33 months from metastatic colon cancer.
  • CONCLUSION: In selected patients, PDT may be useful in the treatment of persistent/recurrent mucosal esophageal cancer after incomplete response to CRT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049021.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


99. Jacob S, Ng W, Asghari R, Delaney GP, Barton MB: Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care. Eur J Cancer; 2009 Sep;45(14):2503-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care.
  • BACKGROUND: Optimal chemotherapy (CT) utilisation rates can serve as benchmarks to assess the quality of cancer care.
  • This study aims to determine the optimal proportion of patients with colon cancer that should receive chemotherapy at least once.
  • RESULTS: Chemotherapy is indicated at least once in 55% of patients with colon cancer.
  • While 89% of colon cancer patients presenting with Stage IV disease should optimally receive chemotherapy, 38-52% actually received chemotherapy as part of their initial treatment.
  • Chemotherapy may be under-utilised in the initial management of patients presenting with metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527926.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


100. Murphy KC: Assessing software impact on clinical workflow and resource utilization. Stud Health Technol Inform; 2009;143:309-14
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The behaviours of two small groups, oncologists and pharmacists, were recorded and analyzed using a case study of patient with metastatic colon cancer.

  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380953.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement